Previous 10 | Next 10 |
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Tuesday, November 2, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and ...
Manuscript highlights MRD negative rate of 69% in the relapsed/refractory patient population Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics’ lead investigational drug, were published online September 16, 2021 in the journal BL...
RenovoRx RNXT +46% after receiving new 510(k) clearance for RenovoCath Delivery System Mechel PAO (NYSE:MTL) +36%. Pliant Therapeutics PLRX +26% on positive PLN-74809 results in Phase 2a IPF study Adaptimmune Therapeutics ADAP +19% and Genentech collaborate to de...
GlycoMimetics, Inc. (GLYC) Q2 2021 Earnings Conference Call August 5, 2021, 8:30 AM ET Company Participants Shari Annes - Investor Relations Rachel King - Chief Executive Officer Eric Feldman - Senior Vice President and Chief Medical Officer Brian Hahn - Senior Vice President and Chief Financ...
Image source: The Motley Fool. GlycoMimetics, inc (NASDAQ: GLYC) Q2 2021 Earnings Call Aug 6, 2021 , 2:00 p.m. ET Operator Continue reading For further details see: GlycoMimetics, inc (GLYC) Q2 2021 Earnings Call Transcript
The following slide deck was published by GlycoMimetics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: GlycoMimetics, Inc. 2021 Q2 - Results - Earnings Call Presentation
GlycoMimetics (NASDAQ:GLYC): Q2 GAAP EPS of -$0.28 beats by $0.03. Cash and cash equivalents of $118.9M Press Release For further details see: GlycoMimetics EPS beats by $0.03
Completion of enrollment is expected by year-end 2021 for the Company-sponsored Phase 3 pivotal trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) Completion of enrollment is expected by year-end 2021 for the Phase 2 portion of the...
GlycoMimetics (NASDAQ:GLYC) announces the appointment of Harout Semerjian as the company's chief executive officer. Semerjian will succeed retiring founding CEO of the company Rachel King. He is a seasoned executive with strong oncology commercialization experience, will lead t...
Mrs. King, the company’s founding CEO, will remain a Director and advisor to support transition GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its Board of Directors has appointed Harout Semerjian as chief executive officer (CEO), effective August 6, 2021, to...
News, Short Squeeze, Breakout and More Instantly...
2024-06-26 06:35:00 ET A Short Guide to Different Order Types With Penny Stocks Understanding the various order types can significantly enhance your strategy when trading penny stocks. Penny stocks represent an exciting opportunity for investors seeking to enter the stock market at ...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 6.8% to $126.09 on volume of 414,790,976 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 18.7% to $0.265 on volume of 162,165,405 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 12.6%...